Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.32 | N/A | +5.88% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.32 | N/A | +5.88% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions affecting performance. They remain committed to their strategic objectives.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term goals despite current setbacks.
Nektar Therapeutics reported a loss per share that was slightly better than expected, but the lack of revenue data and guidance contributed to a negative stock reaction. The stock fell by 4.74% as investors reacted to the cautious tone from management regarding market challenges. The absence of detailed revenue insights may raise concerns about the company's short-term performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Oct 31, 2016